Inovio » About Us » Leadership » Biography

"Vaccines are among the greatest achievements of biomedical science and public health, stimulating protective immune responses against acute and chronic infectious diseases, as well as some infectious diseases that result in cancer."

Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
Journal of the American Medical Association
November, 2007

"I have stated in public seminars that, in my opinion, electroporation is the gold standard for DNA vaccine delivery, giving us the best result in terms of immunogenicity of DNA vaccines."

George N. Pavlakis, MD, PhD
Chief
Human Retrovirus Section, Vaccine Branch
National Cancer Institute

home » about us » leadership » thomas s. edgington

Biography

Thomas S. Edgington, Ph.D.

THOMAS EDGINGTON served as the president and a board member of the Federation of American Societies for Experimental Biology (FASEB). He was founder and Chairman of the Board of Directors of Corvas International, Inc., which was acquired by Dendreon. Dr. Edgington also founded Molecular Biology Consultants Inc., BioSequences Ltd. and NuVas LLC. He served as a director of Apollon, one of the earliest DNA vaccine companies, which was acquired by Wyeth. He served as a member of the scientific advisory board of Halozyme Therapeutics, Inc. Dr. Edgington is a member of the U.S. National Academy of Sciences and the Institute of Medicine. He has over 500 publications in the biomedical sciences and filed over 25 patents.